| Title |
Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, March 2015
|
| DOI | 10.2147/ndt.s80925 |
| Pubmed ID | |
| Authors |
Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain, Altaf Ahmad Malla |
| Abstract |
Patients with schizophrenia suffer high rates of metabolic derangements on some antipsychotic medications that predispose them to cardiovascular diseases. Keeping this fact in mind, we planned this open-label study to see the effect on various metabolic parameters after switching stable schizophrenia subjects, who had developed metabolic syndrome on olanzapine, to aripiprazole. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 90 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 18% |
| Researcher | 16 | 18% |
| Other | 12 | 13% |
| Student > Master | 11 | 12% |
| Student > Bachelor | 7 | 8% |
| Other | 15 | 17% |
| Unknown | 13 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 13% |
| Psychology | 8 | 9% |
| Agricultural and Biological Sciences | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Other | 12 | 13% |
| Unknown | 20 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2024.
All research outputs
#7,959,659
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,035
of 3,132 outputs
Outputs of similar age
#85,220
of 270,992 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#26
of 69 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,992 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.